Medical Condition News

RSS

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the COMPLIANCE trial, a long-term study to compare external event recorders with implantable monitors in patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of post-procedure AF recurrence.

23 Sep 2009

Patient recruitment completed for crucial glioblastoma study

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.

23 Sep 2009

FCI to educate women about fertility preservation

Life-saving cancer treatments such as chemotherapy and radiation can destroy the reproductive potential of both men and women; an added struggle for the 130,000 people in the US diagnosed with cancer each year. The good news is that advances in fertility technologies now give patients the ability to preserve their fertility prior to treatment, an option many oncologists fail to inform their patients.

23 Sep 2009

Obesity can increase cancer incidence in leukemic children

Obesity is an important factor contributing to chemotherapy resistance and increasing relapse rates among children with leukemia, according to recent findings published online first in Cancer Research, a journal of the American Association for Cancer Research.

23 Sep 2009

BioMarin commences PEG-PAL Phase 2 clinical trial for phenylketonuria

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has initiated treatment in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Initial top-line results are expected in mid-2010.

23 Sep 2009

$1.2 million grant to study centrosomes and cilia and their connections to human disease

If you don't know how a human cell is supposed to work, it's hard to offer a good explanation when the cell goes haywire -- as it does in cancer. That's why a Florida State University College of Medicine researcher has been awarded a $1.2 million grant to explore the role of centrosomes and cilia in cell division and development and their connections to human disease.

22 Sep 2009

The YAI Network launches new website to support people with disabilities

The YAI Network (YAI), one of America’s foremost non-profit organizations devoted to creating hope and opportunity for people with developmental and learning disabilities and their families, announced today the introduction of a new Web site at www.yai.org. The new site provides visitors with a crisp and clear presentation of the organization’s mission and opportunities to engage with the network to support people with disabilities as well as access services and information.

22 Sep 2009

Georgia Power Foundation's Michael Anderson honored during the 2009 Community Impact Awards

Atlanta Falcons Defensive End Chauncey Davis recently honored Georgia Power Foundation's Michael Anderson, Aetna's Cynthia Follmer and Camp Kudzu- Georgia's largest camp for kids with diabetes, during the 2009 Community Impact Awards, at the Arthur Blank Family Office.

22 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Narrative exposure therapy is effective for traumatized survivors

A group of German investigators performed a controlled study on psychological help for Rwanda orphans of war. Twenty-six orphans (originally 27) who presented with posttraumatic stress disorder (PTSD) at first assessment continued to meet a PTSD DSM-IV diagnosis 6 months after their initial assessment.

22 Sep 2009

French multicenter study investigates the role of psychotherapy in BPD

A French multicenter study headed by Jean Cottraux (Lyon) has investigated the role of psychotherapy in borderline personality disorder.

22 Sep 2009

A 2,000-mile scooter journey to raise cystic fibrosis awareness

Emily Schaller, a 27-year-old drummer with cystic fibrosis (CF), begins a 2,000-mile journey today aboard a Vespa scooter -- riding from Chicago to Burbank, California, in her quest to get on "The Ellen DeGeneres Show."

22 Sep 2009

Cancer Research UK invests £16 million in new Drug Discovery Programes at Manchester and Glasgow

CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to £16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

22 Sep 2009

Switch programme offers promise for use in youth obesity prevention

The SwitchTM programme, 'Switch what you Do, View, and Chew', has been shown to be capable of promoting children's fruit and vegetable consumption and lowering 'screen time'. Researchers writing in the open access journal BMC Medicine tested the programme and report that it offers promise for use in youth obesity prevention.

22 Sep 2009

Study reveals effectiveness of targeted heat therapy in addition to chemotherapy

Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumours were heated at the time they received chemotherapy, according to new research. The finding bolsters the case for intensifying exploration of the strategy in other types of cancer.

22 Sep 2009

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009

Breast Cancer Action launches "Milking Cancer" campaign against Eli Lilly

Breast Cancer Action (BCA), known as the watchdog of the breast cancer movement, today announced the launch of their "Milking Cancer" campaign challenging the pharmaceutical giant Eli Lilly to stop manufacturing rBGH. rBGH (recombinant bovine growth hormone, also known as rBST) has long been linked to cancer.

22 Sep 2009

Comprehensive and practical overview of psoriasis

Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases).

22 Sep 2009

Austin Retina partners with MVRF to sponsor SupportSight seminar

Austin Retina Associates has joined with the Macula Vision Research Foundation (MVRF) to sponsor a SupportSight seminar in Austin on October 3rd. SupportSight is the national series of educational seminars for people affected by macular degeneration and for those who would like to learn more about this disease affecting more than 25 million people in this country.

22 Sep 2009

Event to address rheumatoid arthritis

26 men and women with RA from across europe honoured as they share their inspirational stories. Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA).

22 Sep 2009